NeuroSense Therapeutics Signs Sales Agreement with JonesTrading
Ticker: NRSNW · Form: 6-K · Filed: Aug 16, 2024 · CIK: 1875091
Sentiment: neutral
Topics: capital-raise, sales-agreement, equity-offering
TL;DR
NeuroSense just inked a deal with JonesTrading to sell shares on demand. Potential cash infusion incoming.
AI Summary
On August 16, 2024, NeuroSense Therapeutics Ltd. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC. This agreement allows NeuroSense to offer and sell its ordinary shares from time to time through the sales agent.
Why It Matters
This agreement provides NeuroSense with a flexible way to raise capital by selling shares, which can be crucial for funding ongoing research and development efforts.
Risk Assessment
Risk Level: medium — The company is entering into a sales agreement to sell shares, which can dilute existing shareholders and is often a sign of needing capital.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Registrant
- JonesTrading Institutional Services LLC (company) — Sales Agent
- August 16, 2024 (date) — Date of Sales Agreement
FAQ
What is the purpose of the Capital on Demand™ Sales Agreement?
The agreement allows NeuroSense Therapeutics Ltd. to offer and sell its ordinary shares, from time to time, to or through JonesTrading Institutional Services LLC, as sales agent.
Who is the sales agent for NeuroSense Therapeutics Ltd. under this agreement?
JonesTrading Institutional Services LLC is the sales agent.
When was the Sales Agreement entered into?
The Sales Agreement was entered into on August 16, 2024.
What type of securities can NeuroSense Therapeutics Ltd. sell under this agreement?
NeuroSense Therapeutics Ltd. may offer and sell ordinary shares, no par value per share.
Does NeuroSense Therapeutics Ltd. file annual reports under Form 20-F or 40-F?
NeuroSense Therapeutics Ltd. indicated that it files annual reports under Form 20-F.
Filing Stats: 897 words · 4 min read · ~3 pages · Grade level 13.9 · Accepted 2024-08-16 16:06:27
Key Financial Figures
- $2,524,437 — of up to gross sale proceeds of up to $$2,524,437. The offer and sale of the Ordinary Sh
Filing Documents
- ea0211530-6k_neurosense.htm (6-K) — 18KB
- ea021153001ex5-1_neurosense.htm (EX-5.1) — 10KB
- ea021153001ex10-1_neurosense.htm (EX-10.1) — 257KB
- ex5-1_001.jpg (GRAPHIC) — 6KB
- ex5-1_002.jpg (GRAPHIC) — 13KB
- 0001213900-24-070239.txt ( ) — 312KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: August 16, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3